VOR BIOPHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.69 USD | -0.59% |
|
-1.17% | -24.89% |
| Mar. 21 | Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating | MT |
| Mar. 21 | Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 433.3 | 436.6 | 152.6 | 115.3 | - | - |
| Enterprise Value (EV) 1 | 433.3 | 206.3 | 156.9 | 131.6 | 63.17 | 7.344 |
| P/E ratio | -5.53 x | -2.85 x | -1.29 x | -1.22 x | -1.25 x | -1.28 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 80.7 x | 11.5 x |
| EV / Revenue | - | - | - | - | 44.2 x | 0.73 x |
| EV / EBITDA | - | -2.27 x | -1.28 x | -1.05 x | -0.42 x | -0.04 x |
| EV / FCF | -5.93 x | -2.2 x | -1.55 x | -1.39 x | -0.7 x | -0.83 x |
| FCF Yield | -16.9% | -45.4% | -64.6% | -72% | -143% | -121% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 37,290 | 65,649 | 67,806 | 68,216 | - | - |
| Reference price 2 | 11.62 | 6.650 | 2.250 | 1.690 | 1.690 | 1.690 |
| Announcement Date | 3/14/22 | 3/23/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 1.429 | 10 |
| EBITDA 1 | - | - | - | -90.89 | -122.5 | -125.5 | -150.9 | -189.7 |
| EBIT 1 | -10.42 | -43.37 | -69.02 | -93.42 | -126 | -108.5 | -121.3 | -117.2 |
| Operating Margin | - | - | - | - | - | - | -8,489.01% | -1,172.04% |
| Earnings before Tax (EBT) 1 | - | -43.34 | -68.9 | -92.09 | -117.9 | -102 | -115.3 | -119.3 |
| Net income 1 | - | -49.26 | -70.13 | -92.09 | -117.9 | -102 | -115.3 | -119.3 |
| Net margin | - | - | - | - | - | - | -8,070.76% | -1,192.64% |
| EPS 2 | -109.8 | -230.6 | -2.100 | -2.330 | -1.750 | -1.389 | -1.350 | -1.316 |
| Free Cash Flow 1 | - | - | -73.04 | -93.61 | -101.4 | -94.67 | -90.51 | -8.86 |
| FCF margin | - | - | - | - | - | - | -6,335.92% | -88.6% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/6/20 | 3/25/21 | 3/14/22 | 3/23/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -18.6 | -18.31 | -22.8 | -21.79 | -24.1 | -24.72 | -30.42 | -32.17 | -35.32 | -28.12 | -27.35 | -27.29 | -27.51 | -27.88 | -26.79 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -18.55 | -18.25 | -22.74 | -21.66 | -23.79 | -23.91 | -28.43 | -29.98 | -33.19 | -26.26 | -25.79 | -25.27 | -25.37 | -25.52 | -25.39 |
| Net income 1 | -18.55 | -18.25 | -22.74 | -21.66 | -23.79 | -23.91 | -28.43 | -29.98 | -33.19 | -26.26 | -25.79 | -25.27 | -25.37 | -25.52 | -25.39 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.5000 | -0.4900 | -0.6100 | -0.5800 | -0.6300 | -0.5300 | -0.4300 | -0.4500 | -0.4900 | -0.3900 | -0.3729 | -0.3491 | -0.3471 | -0.3318 | -0.3140 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/14/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/23/23 | 5/11/23 | 8/10/23 | 11/7/23 | 3/20/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 4.3 | 16.3 | - | - |
| Net Cash position 1 | - | - | 230 | - | - | 52.1 | 108 |
| Leverage (Debt/EBITDA) | - | - | - | -0.0351 x | -0.1298 x | - | - |
| Free Cash Flow 1 | - | -73 | -93.6 | -101 | -94.7 | -90.5 | -8.86 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 4.16 | 3.89 | 8.46 | 1.07 | 4.9 | 4.9 | 5.28 |
| Capex / Sales | - | - | - | - | - | 342.79% | 52.79% |
| Announcement Date | 3/25/21 | 3/14/22 | 3/23/23 | 3/20/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.69
USD
Average target price
14.69
USD
Spread / Average Target
+769.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.89% | 115M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- VOR Stock
- Financials Vor Biopharma Inc.
